Posted by: GOLDMAN007 In reply to: sidesh0wb0b who wrote msg# 30775 Date:3/6/2008 8:05:19 PM Post #of 30791
ONCO the last public Oncology company left the last one was bought out at 32 dollars a share according to EDS
ONCO(0.019)Oncology Med Upgrades Its OTC Market Tier Status to the "Current Information" Category
Thursday, March 06 2008 9:10 AM, EST Market Wire "US Press Releases " PITTSBURGH, PA -- (MARKET WIRE) -- 03/06/08 -- Oncology Med, Inc. (PINKSHEETS: ONCO), a Pittsburgh -based cancer treatment solutions group, announced today that it has upgraded its OTC market tier status to the "Current Information" category by making current information publicly available on the Pink Sheets News Service, in accordance with the Pink Sheets Guidelines for Providing Adequate Current Information. "We have always desired full disclosure so investors can fully understand our Company and its operations," commented Dr. William Walker, CEO of Oncology Med. "We have made tremendous progress in our operations during fiscal year 2007 and we want to continue to inform the investor community of our future results. This puts our Company in one of the top OTC market tiers and will help our Company achieve broader investor interest, increase our respect in the health care community, increase our ability to raise capital on better terms in the capital markets and increase our ability to use our securities as currency for potential accretive acquisitions. We believe that this is a very important step in the evolution of our Company as we continue to strive for growth and shareholder value." About Oncology Med, Inc. Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation treatments to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies. More information about Oncology Med, Inc. can be found at www.oncologymed.com. NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results. For information, please contact: Oncology Med, Inc. Email Contact
Oncology Med, Inc. is a public company engaged in the fulfillment of a variety of services related to the treatment of various cancers. We currently provide analysis and design of radiation treatment plans in order for radiation oncologists to administer various radiation treatment plans to cancer patients. Our services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.
Our mission is to be a pioneer in the advancement of the treatment of cancers. We plan on growing our business through acquisitions in addition to the organic growth of our subsidiary, Comprehensive Physics and Regulatory Services (“CPRS”).
CPRS has pioneered the use of the internet for clinical radiation oncology treatment planning. The service was commenced over ten years ago in an effort to provide cost effective treatment planning by smaller radiation/cancer centers through the sharing of expertise and resources. Medical records including MRI and X-Rays are sent over the internet which allow our staff of physicists and dosemitrists to turn around a fully developed treatment plan in less that 24 hours.
Today our clients range from world class cancer treatment centers to local and regional cancer treatment centers. We have continued to grow in the scope of our services offered and in the geographical areas served, supporting over 25 radiation oncology centers from Florida to New England. Expansion opportunities exist both domestically and internationally.
William J. Walker, Ph.D., CHP , PE Chairman of the Board
Dr. Walker is Chairman of the Board of Oncology Med. Inc., and is President and Chief Executive Officer of Comprehensive Physics & Regulatory Services, Ltd. (“CPRS”). Dr. Walker is a medical physicist with over 40 years of clinical practice, research and program management. He holds a B.S. in Civil Engineering from the Virginia Military Institute, an M.S. in Radiation Biophysics from the University of Kansas, and a Ph. D. from the University of Florida in Environmental Engineering (Medical Physics). He is certified by the American Board of Health Physics, licensed by the State of Florida as a Therapeutic Radiological Physicist and is a registered professional engineer. Dr. Walker retired from the U.S. Air Force in 1978 as a Lt. Col. And was the Chief of Medical Physics for a major USAF Medical Center. Following his retirement from the Air Force, he headed the US Nuclear Regulatory Commission’s medical and academic licensing program and later was the Radiation Safety Officer and Program Director for the National Institute of Health, the largest such program of its kind in the world. He is the author of numerous papers on medical and health physics and a corporate officer and member of the Board of Directors of Advanced Oncology Network, Inc. Dr. Walker is additionally a member of the Boards of Directors of Eureka Cancer Treatment Center, Ltd. and Universal Healthcare Management Systems, Inc.
G. Stephen Brown, M.D., FACR
Dr. Brown is a Professor of Radiation Oncology at the University of Texas M.D. Anderson Cancer Center in Houston. His professional activities are dedicated entirely to peer review and standard applications in Cancer treatments. He received his B.A. in zoology from U.C.L.A. and his M.D. from the University of Ottowa Faculty of Medicine in 1963. After serving a general rotating internship at Cedars-Sinai Medical Center in Los Angeles, he began a 4 year residency in radiation oncology. The first year was at the Cedars – Sinai Medical Center, Los Angeles, CA. The remaining three years were at the Penrose Cancer Hospital in Colorado Springs, CO. The final five months were at the Puerto Rico Nuclear Center in San Juan, Puerto Rico.
After achieving board certification in Therapeutic Radiology from the American Board of Radiology in 1968, he entered practice at the University of Vermont. He served in the U.S. Army Medical Corps at the rank of Major from 1969 to 1972 where he served as Chief of Radiation Therapy and Chief of Nuclear Medicine, Honolulu, Hawaii. He returned to the University of Vermont as Director of Radiation Oncology through 1977. He wss in private practice of radiation oncology from 1977-1990. He was a consultant to the Cancer Department of the World Health Organization from 1990 – 1991. From 1992-1993 he was Associate Director, Division of Cancer Treatment, Radiation Research Branch at the National Cancer Institute. From 1993-1995 he served as Medical Director of Oncology Services Corporation. Since 1995, he has been the Associate Director for Radiation Oncology at the UT M.D..
Mitchell Jarosz, M.S., DABR
Mr. Jarosz received his BS in physics from Duquesne University and attended the Carnegie Mellon Institute for his MS in Radiological Physics. He worked as a staff physicist at St. Francis Medical Center, Pittsburgh, PA for 16 years where he gained experience in commissioning and maintaining various types of radiation therapy equipment,. His experience includes beam data collection, entry and commissioning of treatment planning computers including: ADAC, Multimedia, CMS and Medicalibration PC#D. He is experienced in performing diagnostic calibrations on various x-ray systems including R/F, CT (GE, Elscint, Siemens and Picker), dental ultrasound and mammography units. He has established quality assurance programs and physics protocols for a number of centers for a variety of treatment modalities. He has held course of instruction in diagnostic radiology and nuclear medicine for residents and technologists.
Posts: 6 | Registered: Mar 2008
| IP: Logged |
posted
ONCO is so undervalued and unnoticed by the trading world, IMO. Real company, little debt, revenues, rediculously low float. Once this finally gets noticed, this could fly. Load these cheapies now IMO
Posts: 410 | Registered: Jan 2006
| IP: Logged |
posted
I like it just waiting for some funds to clear and I am going to jump in on this one
Posts: 795 | From: Brown Deer, WI 53223 | Registered: Feb 2004
| IP: Logged |
posted
Good earnings still a net loss but its getting closer to going positive with the cash flow once it does KABOOOOM
Posts: 795 | From: Brown Deer, WI 53223 | Registered: Feb 2004
| IP: Logged |
posted
Oncology Med Announces a 14% Revenue Increase for Fiscal Year 2007 From the Prior Year
Market Wire "US Press Releases "
PITTSBURGH, PA -- (MARKET WIRE) -- 03/10/08 -- Oncology Med, Inc. (PINKSHEETS: ONCO) announced its unaudited results for the fiscal year 2007 shows a 14% increase in revenues to $ 1,745,606.00 from $ 1,536,100.00 for the fiscal year ended 2006. The Company had a net loss of only ($ 76,572.00) for the fiscal year ended 2007 as compared to a net loss of ($ 213,310.00) for fiscal year 2006.
Dr. William J. Walker, chairman of Oncology Med, Inc., stated, "I am extremely pleased with our results for 2007. We have achieved a substantial increase in revenue for fiscal year 2007 over the same period last year. We will have revenues in excess of $ 2,000,000.00 for fiscal year 2008 in addition to achieving net income for the period."
quote:Originally posted by joeyisthebest: Good earnings still a net loss but its getting closer to going positive with the cash flow once it does KABOOOOM
Joey, these are pennies...even coming close to a positive cash is a huge accomplishment. This is truly undervalued.
posted
.016 looks like a great entry point for right now... don't know if I'll pull the trigger but I'll let you all know!
Posts: 858 | Registered: Jul 2005
| IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
![[Smile]](smile.gif)
on this one
